Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 74.7% in August

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 37,252 shares, a decline of 74.7% from the July 30th total of 146,971 shares. Currently, 4.5% of the company’s stock are short sold. Based on an average daily trading volume, of 40,061 shares, the short-interest ratio is currently 0.9 days.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Galmed Pharmaceuticals has a consensus rating of “Sell”.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 76.14% of the company’s stock.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ:GLMD traded down $0.11 during midday trading on Thursday, hitting $4.22. 5,738 shares of the stock were exchanged, compared to its average volume of 185,592. The company has a market capitalization of $4.38 million, a PE ratio of -0.58 and a beta of 0.74. Galmed Pharmaceuticals has a 52-week low of $3.29 and a 52-week high of $13.20. The business’s fifty day simple moving average is $4.47 and its two-hundred day simple moving average is $4.78.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.